🇺🇸 CAEL-101 in United States

9 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

• Window: 22 April 2025 – 22 April 2026
• Total reports: 9

Most-reported reactions

1. Acute Kidney Injury — 1 report (11.11%)
2. Chest Discomfort — 1 report (11.11%)
3. Cough — 1 report (11.11%)
4. Diarrhoea — 1 report (11.11%)
5. Dizziness — 1 report (11.11%)
6. Dyspnoea — 1 report (11.11%)
7. Hyperglycaemia — 1 report (11.11%)
8. Leukocytosis — 1 report (11.11%)
9. Oedema — 1 report (11.11%)

Source database →

Frequently asked questions

Is CAEL-101 approved in United States?

CAEL-101 does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for CAEL-101 in United States?

Alexion Pharmaceuticals, Inc. is the originator. The local marketing authorisation holder may differ — check the official source linked above.